Higher effectiveness than that of CYC. Addresses the issues of relapse commonly associated with CYC. Suggested as the first-line treatment due to its high level of safety and overall success in attaining remission in patients with a level of evidence with GPA and MPA. In patients with EGPA, the level of evidence for rituximab was lower than in GPA/MPA, as evidenced by a retrospective analysis in 41 patients with EGPA. The gene discussed is GYPA; the disease is eosinophilic granulomatosis with polyangiitis.